MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway

MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway

Despite improvements in therapies and screening strategies, lung cancer prognosis still remains dismal, especially for metastatic tumors. Cancer stem cells (CSCs) are endowed with properties such as chemoresistance, dissemination, and stem-like features, that make them one of the main causes of the...

Full description

Bibliographic Details
Main Authors: Massimo Moro, Orazio Fortunato, Giulia Bertolini, Mavis Mensah, Cristina Borzi, Giovanni Centonze, Francesca Andriani, Daniela Di Paolo, Patrizia Perri, Mirco Ponzoni, Ugo Pastorino, Gabriella Sozzi, Mattia Boeri
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Pharmaceuticals
Subjects:
microRNA
lung cancer
cancer stem cell
Online Access:https://www.mdpi.com/1424-8247/15/3/297

Similar Items

Similar Items